Concepedia

Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies

Armin Wolf, Philippe Couttet, Min Dong, Olivier Grenet, Marcia I. Heron, Ursula Junker, U.W. Laengle, David Ledieu, Estelle Marrer, Anja Nussher,

Leukemia Research · 2010 · 69 citations · 23 references

DOI

Concepts

References

23

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

, , +12

A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

Janet D. Rowley · Nature · 1973 · 4.3K citations

, , +17

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Brian Druker, Shu Tamura, Elisabeth Buchdunger et al. · Nature Medicine · 1996 · 3.7K citations

, , +13

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.6K citations · Full text

, , +10

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

, , +13